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The ligand-dependent recruitment of coactivators to peroxisome proliferator-activated receptor-α (PPARα) was examined. PPAR-
binding protein (PBP), PPARγ coactivator-1α (PGC-1α), steroid receptor coactivator-1 (SRC-1),and CBP/p300-interacting trans-
activatorwithED-richtail2(CITED2)aﬀectedPPARαactivityinthepresenceof Wy-14,643.TheeﬀectsonPPARαactivityinlight
of increased or decreased expression of these coactivators were qualitatively diﬀerent depending on the ligand examined. Dimin-
ishedexpressionofPGC-1α,SRC-1,orPBPbyRNAiplasmidsaﬀectednaturalorsyntheticagonistactivitywhereasonlyWy-14,643
was aﬀected by decreased PGC-1α. The interaction of PPARα with an LXXLL-containing peptide library showed ligand-speciﬁc
patterns, indicative of diﬀerences in conformational change. The association of coactivators to PPARα occurs predominantly via
the carboxyl-terminus and mutating 456LHPLL to 456LHPAA resulted in a dominant-negative construct. This research conﬁrms
that coactivator recruitment to PPARα is ligand-dependent and that selective receptor modulators (SRMs) of this important pro-
tein are likely.
Copyright © 2006 Eric S. Tien et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The peroxisome proliferator-activated receptors (PPARs) are
a subfamily of nuclear receptors (NRs) that contains three
members (PPARα, β, γ). These receptors function in a wide
array of metabolic processes including fatty acid and lipid
homeostasis, adipocyte diﬀerentiation, and control of cell
growth and proliferation [1–3]. PPARα responds to a class
of chemicals called peroxisome proliferators (PPs). These
chemicals were so named for the initial ﬁnding that they
caused increases in peroxisome number and size with pro-
longed treatment. Some PPARα ligands promote tumor for-
mation in rodents [4, 5]. Paradoxically, PPARγ ligands have
anticarcinogenic properties in a variety of tissues [6]. An ex-
ample of these compounds is conjugated linoleic acid (CLA),
which is also a ligand for PPARα.
The regulation of gene expression by nuclear receptors
is dependent on the recruitment of accessory proteins to
the transcriptional complex. Coregulators are a class of pro-
teins that function to enhance or repress the activity of the
transcriptional complex around the nuclear receptor dimer.
Coactivators were originally found to contain a speciﬁc se-
quence of amino acids (LXXLL where X is any amino acid)
that was termed the NR box or receptor interacting domain
(RID). Many coactivators contain one or more of these mo-
tifs and use these domains to interact with nuclear receptors
[7, 8]. Though not all coactivators utilize LXXLL to inter-
act with diﬀerent nuclear receptors (such as steroid receptor
RNA activator (SRA) and the CBP/p300-interacting transac-
tivator with ED-rich tail (CITED) family of proteins [9, 10]),
many studies have used LXXLL as a target sequence to iden-
tify more nuclear receptor interacting proteins.
One of the more interesting aspects of the PPAR family
of nuclear receptors is the size of the ligand-binding pocket.
The PPARs have one of the largest ligand-binding domains
by volume of all known nuclear receptors at over 1300 ˚ A3
[11].Bycomparison,theligand-binding pocketoftheliverX
receptor (LXR) is 830 ˚ A3 which is a more typical volume for
nuclear receptors [12]. The size of the ligand-binding pocket
allows the PPARs to accommodate a very wide range of lig-
and shapes and sizes. Known ligands for the PPARs include
hypolipidemic drugs (ﬁbrates), fatty acids (CLA), and plas-
ticizers (phthalates) [13]. The structure of these compounds
varies from compact and steroid-like (ﬁbrates) to long chain
and linear (conjugated linoleic acid (CLA)).
The large number of identiﬁed coactivators has prompt-
edtheworkintodetermininghowproteincomplexesaround
nuclear receptors containing these coactivators are formed.2 PPAR Research
The binding of ligand induces three-dimensional conforma-
tion changes in nuclear receptors [14, 15]. Many coactiva-
tors are recruited to nuclear receptors upon ligand binding
thatsuggeststhattheconformationchangesmaybeexposing
binding sites for coactivators that are unavailable in the ab-
sence of ligand. Unique conformation changes allow for the
recruitment of a speciﬁc group of coactivators in the pres-
ence of a particular ligand, thus allowing for regulation of
a subset of genes in response to the ligand bound. Identify-
ing speciﬁc coactivators that are recruited by PPARα in re-
sponse to diﬀerent ligands would allow for better classiﬁca-
tion of compounds and prediction of gene regulation pat-
terns after exposure to PPs. The ability of PPARα to be acti-
vated by noncarcinogenic compounds such as CLA suggests
that not all PPARα ligands are harmful. A better understand-
ing of how conformational changes in PPARα can inﬂuence
protein complex formation and ultimately aﬀect gene regu-
lation could lead to the development and discovery of other
PPs with potentially beneﬁcial eﬀects on human disease.
In these studies, the ability of PPARα to recruit spe-
ciﬁc coactivators in the presence of diﬀerent ligands was ex-
amined. Initial coactivator screening revealed ligand-speciﬁc
coactivator recruitment. Selective inhibition of the coactiva-
torssteroidreceptor,coactivator(SRC-1),PPARγ coactivator
1α (PGC-1α), and PPAR binding protein (PBP), conﬁrmed
that the ligand-induced transcriptional activity of PPAR is
dependent on the recruitment of speciﬁc coactivator com-
plexes. Limited protease digestion and peptide mapping re-
vealed that PPARα undergoes conformational changes in re-
sponse to ligands and that not all these conformations are
the same. A closer examination of the PPARα amino acid se-
quence identiﬁed an internal LXXLL motif that can interact
with other domains within the receptor, suggesting it is in-
volved in protein folding. Mutation of this NR box resulted
in a loss of ligand-induced transcriptional activity. This mu-
tationdidnotcausealossofbindingtoDNAordimerization
with RXRα. These results suggest that activation of PPARα is
dependent on ligand-induced conformation changes allow-
ing for the recruitment of unique transcriptional complexes
around the PPAR-RXRα heterodimer.
EXPERIMENTAL
Materials
Wy-14,643 ([4-chloro-6-(2,3-xylindino)-2-pyrimidinylthio]
aceticacid,CASNo.50892-23-4,> 98%pure)waspurchased
from Chemsyn Science Laboratories (Lenexa, KS). ETYA (5,
8,11,14-Eicosatetraynoic acid), MK886, and PGJ2 were pur-
chased from Biomol (Plymouth Meeting, PA). Bezaﬁbrate,
cloﬁbric acid, ciproﬁbrate, dimethylsulfoxide (DMSO), and
all other chemicals were obtained from Sigma (St Louis,
MO). Media components were from Invitrogen (Carlsbad,
CA).Fetalbovineserum(FBS)waspurchasedfromHyClone
Laboratories (Logan, UT). Components for real-time PCR
were purchased from Applied Biosystems (ABI, Foster City,
CA). Plasmid puriﬁcation kits were purchased from Qiagen
(Chatsworth, CA). All oligos were purchased from Operon
(Alameda, CA). Other chemicals and reagents were of the
highest grade readily available.
Plasmids
pFR-luciferase (UAS luciferase, Gal4 response element)
was purchased from BD Biosciences Clontech (Palo Alto,
CA). pRL-TK Renilla (pRL-TK), pRL-CMV Renilla (pRL-
CMV), pSV-β-Gal, and pGEM-T Easy were purchased from
Promega (Madison, WI). The construction of pM/PPARα
constructs was described previously [16]. The PPAR re-
sponseelementreporter,pACO(−581/−471)G.Lucwassup-
plied by Dr Jonathon Tugwood (Zeneca Pharmaceuticals,
Central Toxicology Laboratories, Maccelsﬁeld, UK) and has
been previously described [17]. The last 30 amino acids of
PPARα were ampliﬁed using PCR with a 5  BamHI and 3 
SalI restriction sites. Fragment was cloned into the pVP16
vector (Clontech, Palo Alto, CA).
Cellculture
The COS-1 cells were maintained in α-MEM with 8% FBS
and with 1% penicillin/streptomycin. 3T3L1 preadipocytes
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) with 4.5g/L D-glucose, 10% FBS, and 1% peni-
cillin/streptomycin.
Transfectionandreporterassays
All transient transfections were performed using Lipofec-
tAMINE (Invitrogen, Carlsbad, CA) according to the man-
ufacturer protocol. Transfections were carried out in 24
well plates with cells plated at 50000 cells per well and
allowed to recover overnight before transfection. Peptide
library was obtained as a gift from Chang et al [18].
Four hundred μg/well of GAL4DBD fusion plasmids or
corresponding expression plasmid were transfected with
100μg/well of reporter (PPRE driven or GAL4 driven) and
100μg/well transfection eﬃciency control (pRL-TK). Four
hundred μg/well of RNAi plasmid was used for inhibition
experiments. All mammalian-2-hybrid experiments used
400μg/wellVP16ADfusionplasmid.Ineachexperiment,the
total amount of DNA transfected per well was held constant
using empty vector plasmid (pcDNA3). RNA inhibitor ex-
periments were performed in the same manner.
Proteasedigestion
FulllengthratPPARαwasinvitrotranslatedandlabeledwith
S35-methionine and puriﬁed using Chromaspin columns
(Clontech, Palo Alto, CA) to remove unincorporated ra-
dionucleotide. Puriﬁed, radiolabeled protein was concen-
trated using Centricon 20 concentrators (Millipore, Biller-
ica, MA) and quantitated using a scintillation counter to
ensure adequate labeling. PPARα was bound to the lig-
and for 30 minutes at room temperature and then digested
with 50μg/mL of α-chymotrypsin for 20 minutes at roomEric S. Tien et al 3
Table 1 :T a r g e ts e q u e n c e sf o rc o a c t i v a t o rR N A i .
Gene RNAi sequence Accession
SRC-1 5 -gttgtccgtgtaattgacc-3  U64828
PBP 5 -gactgcctctcctatcatt-3  NM 134027
PGC-1α 5 -agacgtccctgctcagagc-3  NM 008904
temperature. Resulting digests were resolved on an 18% tris-
glycine gel. The gel was dried and subjected to autoradiogra-
phy.
SmallinhibitorRNA(RNAi)plasmids
All RNAi plasmids were made in pSUPER.neo (OligoEngine,
Seattle, WA). Target sequences were chosen according to the
manufacturer protocol and are listed in Table 1. Oligos were
annealed and phosphorylated also according to the manu-
facturer protocol and cloned into linearized vector that was
digested with BglII and HindIII.
Statisticalanalysis
Where indicated, the MiniTab (State College, PA) was used
to evaluate data for statistical signiﬁcance using one-way
ANOVA and Tukey’s multicomparison test with signiﬁcance
at P<. 05.
RESULTS
Identiﬁcationofligand-speciﬁcPPARαcoactivators
AninitialscreenofsomeknownPPARαcoactivatorsrevealed
diﬀerential activation in the presence of vehicle (DMSO),
Wy-14,643, and CLA (Figure 1). Over expressing the RNA
coactivator SRA increased the basal activity of PPARα and
CLA induction, but had no eﬀect on Wy-14,643 activity.
Conversely, the CBP/p300 interacting protein CITED2 in-
creasedPPARαactivityinthepresenceofCLAwithamodest,
nonsigniﬁcant increase in the presence of Wy-14,643. The
LXXLL-containing coactivator PBP did not increase the ac-
tivity of PPARα in the presence of either of the activators.
This ﬁnding prompted a closer examination of the eﬀect
of ligand binding on the recruitment of coactivators to the
PPARα transcriptional complex.
TargetedinhibitionofPPARαcoactivators
RNA inhibition (RNAi) has become a useful tool to selec-
tively reduce the expression of target proteins from the cel-
lular environment. RNAi sequences were designed for three
known PPARα coactivators: PBP, PGC-1α, and SRC-1. The
chosen RNAi sequences were cloned into an expression plas-
mid that is driven by the RNAH1 promoter to generate dou-
ble stranded hairpin RNA molecules. As shown in Figure 2,
the basal activity of PPARα was reduced with each coacti-
vator RNAi. Interestingly, only the inhibition of PGC-1α re-
sulted in a signiﬁcant decrease in Wy-14,643 or ciproﬁbrate
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Figure 1: Eﬀects of various coactivators on the activation of PPARα
by Wy-14,643 and CLA. COS-1 cells were transiently transfected
with pM/PPARα, GAL4 reporter, and coactivator expression plas-
mids or empty vector control (total DNA per well was held con-
stant).Cellsweretreatedfor6hourswith50μMWy-14,643,100μM
CLA, or DMSO. Luciferase activity was measured and corrected for
transfection eﬃciency and extraction yield (n = 3). Relative values
are corrected to untreated pcDNA3 bar (100%). Bars with diﬀer-
ent letters above are signiﬁcantly diﬀerent from each other (Tukey’s
multicomparison test, P<. 05), representative of 2 independent ex-
periments.
activation of PPARα (when compared to the pcDNA3 trans-
fected cells). Induction by CLA or ciproﬁbrate was lost with
each coactivator RNAi. Under these conditions the expres-
sion of the three coactivators was reduced to approximately
50% of that of the control plasmid-transfected cells (data not
shown).
Examinationofligand-inducedconformation
changesinPPARα
One possible mechanism behind the ligand-speciﬁc coac-
tivator recruitment seen in the transient transfection and
RNAi studies is the induction of unique conformational
changes in PPARα. Ample evidence shows that nuclear re-
ceptors will undergo conformation changes when bound
to ligand [14, 15]. To examine this phenomenon, limited
protease digestion was performed using in vitro translated
PPARα. As shown in Figure 3, protease digestion of Wy-
14,643-activated PPARα produced a banding pattern of di-
gestion products that was diﬀerent from that of unactivated
(DMSO) and CLA activated PPARα. Other compounds were
tested in this manner. The PPARγ speciﬁc activator PGJ2 and
the PPARα antagonist MK886 lead to a pattern similar to
that of DMSO (data not shown). In addition, other proteases
and digestion conditions were attempted with little improve-
ment in resolution. The identiﬁcation of a detectable change4 PPAR Research
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Figure 2: Inhibition of coactivator expression by RNAi decreases
PPARα activity in a ligand-speciﬁc manner. 3T3L1 cells were tran-
siently transfected with pM/PPARα,G A L 4r e s p o n s i v er e p o r t e r ,
pRLTK, and appropriate RNAi vector or empty vector control. Cells
were treated with 50μM Wy-14,643, 100μM CLA, 100μM ciproﬁ-
brate, or DMSO for 6 hours. Luciferase activity was measured and
corrected for transfection eﬃciency and extraction yield (n = 3).
Values are expressed corrected to untreated empty vector control
bar (100%). Bars with diﬀerent letters above are signiﬁcantly diﬀer-
ent from each other (Tukey’s multicomparison test, P<. 05), repre-
sentative of 2 independent experiments.
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Figure 3: Protease digestion of in vitro translated PPARα.R a t
PPARαwasinvitrotranslatedandlabeledwithS35 methionine.Un-
incorporated S35 was removed with size exclusion resin and the la-
beled protein was concentrated. Yield was determined and 10fmol
of PPARα were used in each digestion. PPARα was bound to the
ligand for 30 minutes at 22◦C and then digested with 50μg/mL of
α-chymotrypsin for 20 minutes at 22◦C. Resulting digests were re-
solved on an 18% tris-glycine gel. The constant product is shown
with the dark arrow and the Wy-14,643-protected fragments are
shown with light arrows, representative of 3 independent experi-
ments.
in the conformation of PPARα in response to a known lig-
and suggested that PPARα does indeed undergo conforma-
tionchanges.Wethensoughttoﬁndamoresensitivemethod
of evaluating these conformational changes.
Chang et al previously developed a library of randomly
designedLXXLLcontainingpeptideswhichwerefusedtothe
GAL4-DNA binding domain (DBD) and used to create in-
teraction maps for the estrogen receptor (ER) [18]. This li-
brary was used to screen potential peptides that interact with
PPARα using a VP16/PPARα fusion (Figure 4). Hierarchical
clusteringwasusedtocomparethesimilaritybetweenthein-
teraction patterns between PPARα activated by several xeno-
biotic or natural ligands. Interestingly, the pattern of peptide
recruitment to xenobiotic-liganded PPARα was dissimilar.
Wy-14,643 was most like docohexaenoic acid (DHA) and α-
linolenic acid (ALA) while ciproﬁbrate’s interaction pattern
resembled that of CLA (Panel (a)). A smaller subset of pep-
tides was examined for a variety of xenobiotics (Panel (b)).
This limited set of LXXLL peptides was able to discriminate
between strong (Wy and ETYA), moderate (CLA and bezaﬁ-
brate),andweak(cloﬁbrate)agonists.Thesestudiesshowthe
utility of the peptide libraries in mapping conformational
change, as well as depicting a potential reason for diﬀerences
in coactivator recruitment between Wy-14,643 and CLA as
shown above.
RoleofPPARα’sLXXLLmotifin
coactivatorrecruitment
Examination of the amino acid sequence of the PPARs across
all subtypes and species revealed a highly conserved LXXLL
(456LHPLL) motif in the carboxy-terminal end of the protein
in helix 12, a region of the NRs involved in conformational
change and coactivator recruitment [12]. Targeted mutage-
nesis of 456LHPLL to 456LHPAA in full length PPARα (des-
ignated 2LA) resulted in reduced Wy-14,643-mediated re-
sponse of a PPRE-driven reporter construct (Figure 5(a)).
Wy-14,643 increased reporter activity nearly 6-fold in wild
type PPARα versus 2-fold for the 2LA mutant. To further
characterize this loss of activity, the ability of the 2LA mu-
tant to interact with the PPARα dimer partner RXRα was ex-
amined. As shown in Figure 5(b), the wild type PPARα can
interact with RXRα in the presence and absence of exoge-
nous ligand. Wy-14,643 increased the interaction between
PPARα and RXRα in the wild type PPARα by approximately
3 fold. Interestingly, the 2LA mutant was unable to interact
withRXRintheabsenceofligand.WiththePPARα2LAcon-
struct, Wy-14,643 increased the association with RXRα by
greaterthan14-fold.Thus,2LAisabletointeractwithRXRα,
though not in exactly the same manner as wild type. Given
thatthe2LAmutantisabletoperformmanyofthefunctions
seen with wild type PPARα but shows reduced induction by
agonist, it was hypothesized that the 2LA mutant may act as
a dominant negative of PPARα activity. The addition of in-
creasing amounts of 2LA mutant with a constant amount of
wild type PPARα resulted in a dose-dependent decrease in
PPARα transcriptional activity (Figure 5(c)).Eric S. Tien et al 5
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Figure 4:InteractionbetweenLXXLLpeptidesandPPARαinmammaliantwo-hybridassay.COS-1cellsweregrowninserum-freemediafor
12 hours before transfection with GAL4DBD(pM)/peptide fusions, VP16/PPARα, pFR-luciferase, and pRL-TK. Panel (a): cells were treated
with 100μM α-linolenic acid (ALA), linoleic acid (LA), docosahexaenoic acid (DHA), conjugated linoleic acid (CLA), octanoic acid (OCT),
oleic acid (OA), 25μM Wy-14,643 (Wy), 25μM ciproﬁbrate (Cipro), or DMSO (0.1%v/v) for 6 hours. Panel (b): cells were transfected and
t r e a t e da sd e s c ri b e da b o v ewi t hD M S O ,C L A ,W y ,a n da l s owi t h1 0 0μM eicosatetraynoic acid (ETYA), bezaﬁbrate (Beza), or cloﬁbrate (Clo).
Luciferase activity was measured and corrected for extraction yield and transfection eﬃciency (n = 3). Data was expressed relative to that
of the pM-empty construct and the presented heat map was generated in GeneSpring (Agilent, Palo Alto, CA). Darker shading represents
higher luciferase activity.
RoleofPPARα’sLXXLLmotifinintra-and
intermolecularinteraction
Since many coregulators use the LXXLL motif to interact
with PPARα, we examined whether 456LHPLL could in-
teract with full-length PPARα and form an intramolecu-
lar association. The last 30 amino acids of PPARα were
fused to the VP16AD and used in a mammalian-2-hybrid
with full-length PPARα fused to the GAL4DBD. As shown
in Figure 6(a), 456LHPLL can interact with the full-length
PPARα receptor in the presence of ligand. Mutation of
456LHPLLto 456LHPAAresultedinnointeractioninthepres-
ence of ligand (data not shown). The interaction between
PPARα and 456LHPLL was mapped using mammalian-2-
hybrid.Theinteractionoccurredbetween 456LHPLLandpri-
marily the E/F domain with some interaction occurring with
the D domain (Figure 6(b)). A repression of A/B basal activ-
ity was also seen with the addition of VP16AD-456LHPLL. A
full-length PPARα with a mutated 456LHPLL (2LA) was able
to interact with the PPARα 456LHPLL fragment in the pres-
ence or absence of ligand (Figure 6(c)) but there was still no
activation by Wy-14,643. In addition, the 456LHPLL is able
to interact with receptor interacting domains 1 and 2 (RID1
and RID2) of SRC-1 (data not shown). These results show
that PPARα is able to interact with its own LXXLL motif and
that the 456LHPLL motif in PPARα can interact with other
LXXLL containing proteins.
DISCUSSION
The recruitment of coactivators by nuclear receptor tran-
scriptional complexes is an essential part of gene regulation
through these proteins. In the presence of Wy-14,643, PBP
and SRA were unable to increase the transcriptional activity
of PPARα. In the presence of CLA, however, both PBP and
SRA did increase the transcriptional activity of PPARα.C o n -
versely, another known PPARα coactivator, CITED2 [19],
increased PPARα activity in the presence of both CLA and
Wy-14,643. These results suggested that coactivator recruit-
ment by PPARα might depend on the identity of the ligand
which is activating PPARα and that not all known coactiva-
tors of PPARα are recruited upon receptor activation. This
phenomenonhasbeenobservedwithPPARγ whereallmem-
bersofthep160familywererecruitedinthepresenceofPGJ2
but none were recruited in the presence of troglitazone [20].
Selective inhibition of PPARα coactivators was achieved
through the use of RNAi plasmids. Inhibition of PGC-1α re-
sulted in a signiﬁcant decrease in Wy-14,643 activation of
PPARα, a loss of CLA induction, and a decrease in ciproﬁ-
brate induction. Conversely, inhibition of SRC-1 and PBP
did not have a signiﬁcant eﬀect on Wy-14,643 induction but
did decrease CLA and ciproﬁbrate induction of PPARα.T h e
lack of signiﬁcant eﬀect upon PBP inhibition is in agreement
with initial coactivator screens using overexpression of PBP
in which PBP was only able to increase the activity of CLA6 PPAR Research
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Figure 5: Mutation of 456LHPLL in PPARα decreases PP-induced transcriptional activity. Panel (a): 456LHPLL of rat PPARα was mutated to
456LHPAA (mutant designated 2LA) using site-directed mutagenesis. COS-1 cells were transiently transfected with wild type or 2LA mutant
PPARα, a PPRE driven luciferase, and transfection eﬃciency control. Cells were treated for 6 hours with 50μM Wy-14,643 and assayed
for luciferase activity which was corrected for transfection eﬃciency and extraction yield (n = 3 ) .R e l a t i v el u c i f e r a s el e v e l sw e r ec o r r e c t e d
to wild type untreated bar (100%). Bars with diﬀerent letters above are signiﬁcantly diﬀerent from each other (Tukey’s multicomparison
test, P<. 05). Panel (b): COS-1 cells were transiently transfected with PPARα wild type and 2LA mutant and were fused to the GAL4DBD
and transfected with VP16AD fused to the RXRα or empty vector. As noted on the axis, PPAR-VP16 is a cotransfection of pM/PPARα and
empty VP16AD vector. Cells were treated with 50μM Wy-14,643 for 6 hours. Luciferase activity was measured and corrected for transfection
eﬃciency and extraction yield (n = 3). Relative luciferase levels were corrected to wild type VP16 untreated bar (100%) and plotted along a
log y-axis to allow for ease of viewing. Bars with diﬀerent letters above are signiﬁcantly diﬀerent from each other (Tukey’s multicomparison
test, P<. 05). Panel (c): COS-1 cells were transiently transfected with a constant amount of wild type PPARα expression plasmid, a PPRE-
driven reporter with increasing amounts of 2LA mutant expression plasmid. Total DNA transfected per well was held constant. Cells were
untreated and assayed for luciferase activity and corrected for transfection eﬃciency and extraction yield (n = 3). Relative luciferase activity
was corrected to the no mutant values (100%). ∗P<. 05 compared to 0μg 2LA mutant plasmid data point, representative of 2 independent
experiments.
and had no eﬀect in the presence of Wy-14,643. In addi-
tion, analyzing the data as fold induction of luciferase activ-
ity over DMSO control for each coactivator RNAi resulted
in the same conclusion. These results suggest that PGC-1α is
more vital to the overall activity of the transcriptional com-
plex than SRC-1 or PBP. While initially surprising, the ability
of PPARα to overcome the inhibition of SRC-1 suggests that
PPARαmayberecruitinganothermemberofthep160family
of coactivators. All three known members of the p160 family
of coactivators are reasonably well conserved and the viabil-
ity of the SRC-1 knockout mouse further suggests that SRC-
1 may not be as essential to nuclear receptor transcriptional
complexes as originally thought [21]. Currently, creation of
celllinesthatharborstableinhibitionsofthesecoactivatorsis
being pursued. These cells lines will be used to further exam-
ine the potential impact of coactivator inhibition on gene ex-
pressionandtoattempttoidentifygenesthatarecoactivator-
d e p e n d e n ta sw e l la sP P A R α-dependent.
Changes in the structure of PPARα may constitute a
part of the mechanism behind ligand-speciﬁc coactivator re-
cruitment. Alterations in the three-dimensional structure of
the receptor in the activated versus unactivated state is not
a novel concept. Conformation changes induced by ligand
bindingtonuclearreceptorshasbeenpreviouslyreportedforEric S. Tien et al 7
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Figure 6: Intramolecular interaction of PPARα LXXLL motif. Panel (a): 456LHPLL of wild type PPARα was fused to the VP16AD and used
in a mammalian-2-hybrid assay with pM/PPARα. COS-1 cells were transfected and treated with 50μM Wy-14,643 for 6 hours. Luciferase
activity was measured and corrected for transfection eﬃciency and extraction yield (n = 3). Bars are standardized to the pVP16 DMSO
control bar (100%). Bars with diﬀerent letters above are signiﬁcantly diﬀerent from each other (Tukey’s multicomparison test, P<. 05).
Panel (b): COS-1 cells were transiently transfected with GAL4DBD fusions of PPARα or each domain with VP16AD-456LHPLL or empty
vector control. Luciferase values were measured and corrected for transfection eﬃciency and extraction yield (n = 3). Bars are standardized
to untreated VP16 value for each domain individually (100%). Bars with diﬀerent letters above are signiﬁcantly diﬀerent from each other
(Tukey’s multicomparison test, P<0.05). Panel (c): COS-1 cells were transiently transfected with PPARα wild type and 2LA mutant and
were fused to the GAL4DBD and transfected with VP16AD fused to 456LHPLL or empty vector. Cells were treated with 50μM Wy-14,643
for 6 hours. Luciferase activity was measured and corrected for transfection eﬃciency and extraction yield (n = 3). Relative luciferase levels
were corrected to wild type VP16 untreated bar (100%). Bars are graphed on a log scale along the y-axis to facilitate viewing. Bars with
diﬀerent letters above are signiﬁcantly diﬀerent from each other (Tukey’s multicomparison test, P<. 05), representative of 2 independent
experiments.
estrogen receptor and glucocorticoid receptor [14, 22, 23].
Using limited protease digestion, the binding of PPARα to
Wy-14,643 induced a unique conformation compared to
other known PPARα ligands suggesting that not all ligands
aﬀectPPARα3Dconformationinthesamemanner.Thesen-
sitivity of this technique, however, does not allow for closer
examination of subtle changes in conformation. In an at-
tempt to more closely examine the conformational changes
in PPARα, a random LXXLL-containing peptide library was
used. Previously, this library of LXXLL containing peptides
of lengths between 19 and 22 amino acids was used to
map the conformation of the estrogen receptors [18]. Our
analysis showed that three compounds, Wy-14,643, bezaﬁ-
brate, and CLA, induced the most similar conformation
change in PPARα. Interestingly, a compound closely related
to bezaﬁbrate, cloﬁbrate induced the most dissimilar con-
formation change in PPARα compared to Wy-14,643 and
bezaﬁbrate.8 PPAR Research
While cloﬁbrate is the original compound used, cloﬁb-
ric acid is the active metabolic product. Both cloﬁbrate and
bezaﬁbrateareﬁbrateclasshypolipidemicdrugsandarebuilt
upon the same phenol chemical backbone. The metabolism
of cloﬁbrate to cloﬁbric acid appears to change the struc-
ture of the compound enough to allow PPARα to discrimi-
nate between the two. While bezaﬁbrate and cloﬁbrate both
induce fatty acid oxidation enzymes [24], not all of the ef-
fects of these compounds are the same with regard to lipid
metabolism. Bezaﬁbrate reduces plasma apolipoprotein CIII
(apoCIII) and triglyceride levels, while cloﬁbrate does not
[25]. ApoCIII is associated with the development of diabetes
and a high level of apoCIII is used as a marker for hyper-
triglyceridemia which poses a cardiovascular risk [26, 27].
While compounds designed for the same purpose will in-
evitably exhibit minor diﬀerences in gene expression, the in-
ability of cloﬁbrate to regulate apoCIII compared to bezaﬁ-
brate may be one reason that cloﬁbrate has become a less
used treatment to date. Thus, even compounds designed for
the same function induce diﬀerential gene expression. This
is of concern when designing novel pharmaceuticals and the
mapping of the conformational changes in the PPARs may
allow for the prediction of gene regulation and reveal po-
tential unpredicted eﬀects based on gene expression pat-
tern.
It is clear that while the structural changes within PPARα
are playing a role in ligand discrimination, the potential
conformational changes that involve coactivator recruitment
are less deﬁned. A closer examination of the amino acid se-
quence of the PPARs revealed an LXXLL motif (456LHPLL)
in the carboxy terminal end of all known PPARs regardless of
species or subtype. Mutation of 456LHPLL in the full length
PPARα to 456LHPAA (designated 2LA) results in a receptor
that is unable to be transcriptionally activated by Wy-14,643
and functions as a dominant negative for PPARα. The domi-
nant negative function of this mutation could come from ei-
ther sequestration of RXRα or occupation of the PPRE with-
out regulation of gene expression and blocking of wild type
PPARαbinding.Dominantnegativeshavebeenidentiﬁedfor
coactivators like ARA54 and nuclear receptors including AR
and ER [28–30] and have been used to further dissect the ac-
tivity of wild type proteins. The presence of an LXXLL motif
within PPARα suggests the possibility that PPARα may func-
tion as a coactivator as well. Other nuclear receptors such as
SHP-1 inﬂuence gene expression without directly binding to
DNA [31]. With a classic coactivator recognition sequence,
other transcription complexes could use 456LHPLL to recruit
PPARα and PPARα associated proteins.
Inaddition,PPARαisabletointeractwithitsownLXXLL
motif suggesting that these residues in the E/F domain are
important for the conformation of PPARα. Since the bind-
ing of the PPARα LXXLL occurs within the E/F domain
as shown by mammalian-2-hybrid mapping, it can be con-
cluded that the intramolecular LXXLL interaction may pre-
vent the binding of other LXXLL containing peptides in the
absence of ligand, possibly even helping to properly form the
ligand-binding pocket. Mutation of the LXXLL motif within
PPARαcouldbedisruptingtheformationofligandaccepting
conformationandleadtoareceptorwhichisunresponsiveto
ligand activation.
The results described here show that PPARα ligands can
induce unique conformation changes in the receptor and
that these changes allow for the recruitment of a speciﬁc
coactivatorcomplexaroundtheheterodimertoregulategene
expression. These conformation changes appear to involve
the LXXLL motif contained within a highly conserved helix
12 region of PPARα. The fact that this LXXLL motif is con-
servedacrossallPPARsubtypesandspeciessuggeststhatthis
motif plays a role in the overall functioning of the PPARs. A
possiblefunctionofthismotifcouldincludethepotentialfor
PPARs to act as an LXXLL containing protein rather than as
a pure transcription factor thus allowing PPARs to act indi-
rectly in the regulation of gene expression, possibly as part
of other protein complexes. The likelihood of this possibility,
however, is unclear at this point and more work is needed
to delineate this hypothesis further. Unique protein complex
f o r m a t i o na r o u n dP P A R α in response to diﬀerent activators
revealsamechanismbehindhowdiﬀerentligandsforPPARα
can have such varied eﬀects (carcinogen versus noncarcino-
gen) and how PPARα can diﬀerentiate between ligands and
regulate gene expression accordingly. A better understanding
of complex formation could lead to the discovery of more
PPARα ligands that have beneﬁcial eﬀects for the prevention
and treatment of human diseases.
ABBREVIATIONS
NR Nuclear receptor
PPAR Peroxisome proliferator-activated receptor
PPRE Peroxisome proliferator responsive element
PPs Peroxisome proliferators
PBP PPAR binding protein
PGC-1α PPARγ coactivator 1α
SRC-1 steroid receptor coactivator-1
CITED2 CBP/p300-interacting transactivator
with ED-rich tail 2
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